Report from other groups showed that GBM tumors positive for the ligands of IL-13Rα2 (i.e., CHI3L1/YKL40) and EGFRvIII are also clinically more aggressive compared to tumors lacking both molecular markers6, thus, suggesting a possible relationship between EGFRvIII/IL-13Rα2 and its ligand CHI3L1. The gene discussed is IL13RA2; the disease is glioblastoma.